A groundbreaking advancement in studying the peripheral nervous system (PNS) has emerged through the development of a new chemogenetic tool. The PNS plays a crucial role in regulating vital processes like digestion, secretion, pancreatic function, liver metabolism, and visceral pain signaling.
A groundbreaking advancement in studying the peripheral nervous system (PNS) has emerged through the development of a new chemogenetic tool. The PNS plays a crucial role in regulating vital processes like digestion, secretion, pancreatic function, liver metabolism, and visceral pain signaling. Precision tools are essential for understanding PNS activity and designing therapies for disorders involving the gut–nerve interface. While Designer Receptors Exclusively Activated by Designer Drugs (DREADDs) have been widely used in the central nervous system (CNS), their application in the PNS has faced challenges due to off-target effects and activation limitations.
Kang et al. addressed these issues by re-engineering the hydroxycarboxylic acid receptor 2 (HCAD2), a Gαi-coupled receptor predominantly expressed in peripheral nerves, into a PNS-specific DREADD. Using cryogenic electron microscopy (cryo-EM), the team designed a selective actuator molecule, FCH, tailored to activate HCAD2 without crossing the blood–brain barrier. This innovation ensures peripheral specificity, avoiding central side effects. Experimental validation in mouse models demonstrated that FCH administration suppressed neural activation and reduced acute and chronic pain responses caused by mechanical, heat, and inflammatory stimuli.
This system provides a precise tool for studying PNS-driven processes such as digestion, metabolism, and gut–brain communication while offering therapeutic potential for visceral pain, metabolic regulation, and gastrointestinal motility disorders. Despite challenges like ensuring receptor inertness without ligand exposure and minimizing off-target effects, this platform marks a significant leap in expanding chemogenetic tools beyond the brain, paving the way for targeted treatments of PNS-related diseases.
This review redefines dopamine (DA) signaling beyond its classical role in reward processing, positioning dopaminergic circuits as central regulators of feeding behavior, metabolic sensing, and energy homeostasis. The authors describe how distributed dopamine ensembles across...
Introduction Atherosclerosis has traditionally been viewed as a lipid-driven disease. However, emerging evidence highlights a critical role of chronic inflammation and immune activation, with the gut microbiota now recognised as a key modulator of vascular...
Clinical Summary In this randomized international trial (COBRRA), investigators compared the bleeding risk of apixaban vs. rivaroxaban in patients with acute venous thromboembolism (VTE), including pulmonary embolism and proximal deep-vein thrombosis. A total of 2,760...
The American College of Gastroenterology (ACG) 2025 meeting is a prominent annual event where groundbreaking research, clinical studies, and advancements in gastroenterology are presented. At the ACG 2025 meeting, several impactful studies were showcased, providing...
Alcohol Use Disorder (AUD) and Alcohol-Related Liver Disease (ArLD) often coexist, presenting a complex clinical challenge that requires careful consideration of pharmacological treatment. Below is a detailed explanation starting from definitions, the need for pharmacological...
Copper dysregulation plays a central role in the pathogenesis of Wilson disease (WD). The disease arises from the body’s inability to regulate copper levels, leading to its accumulation and subsequent toxicity. Below is a detailed...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.